191 Quality of Life Improvements in Persistent Asthma Subjects Receiving Combined Mometasone Furoate and Formoterol

AUC0–12h values with MF/F 200/10 mg, MF/F 400/10 mg, and MF 400 mg correspond to average hourly increases of 0.30, 0.35, and 0.17 L, respectively. MF/F was associated with a rapid (,5 minutes) and sustained improvement in lung function. The percentages of subjects experiencing an asthma deterioration (ie, severe asthma exacerbation) were 12.4% (MF/F 200/10 mg), 12.2% (MF/F 400/10 mg), and 18.3% (MF 400 mg). There were no notable differences in AEs between the groups. Conclusions: Both the 200/10 mg BID and 400/10 mg BID doses of MF/F combination therapy led to significantly greater improvements in lung function compared with 400 mg BID MF monotherapy in subjects with severe asthma previously treated with an ICS alone or in combination with LABA.